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Abstract The transport of antigenic peptides from the cytosol
to the lumen of the endoplasmic reticulum (ER) is an essential
process for presentation to cytotoxic T-lymphocytes. The
transporter associated with antigen processing (TAP) is respon-
sible for the intracellular translocation of peptides across the
membrane of the ER. Efficient assembly of MHC-peptide
complex requires the formation of a macromolecular transport
and chaperone complex composed of TAP, tapasin and MHC
class I molecules. Therefore, structure and function of TAP is
important for the understanding of the immune surveillance.
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1. Introduction
Presentation of antigenic peptides by MHC class I mole-
cules to cytotoxic T-lymphocytes (CTL) is an essential process
for the cellular immune recognition. These peptides are pri-
marily generated by the proteasome complex, a multisubunit,
multicatalytic protease (for review see [1]), and are translo-
cated from the cytosol into the lumen of the endoplasmic
reticulum (ER) by a so-called transporter associated with anti-
gen processing (TAP). In the ER, the peptides are loaded onto
the newly synthesized MHC class I molecules. Binding of the
peptide stabilizes the complex and induces the export to the
cell surface for presentation to T cell receptors (Fig. 1A). The
class I heterotrimer consists of an MHC encoded heavy chain,
L2-microglobulin and peptide and its assembly is well studied
(for review see [2,3]). However, less is known of how the
peptides are transported into the ER. Some open questions
still remain: The amount and quality of peptides generated by
the proteasome, the mechanism of the transport as well as the
involvement of other factors such as additional chaperones,
proteases or transporters. The availability of peptides to the
MHC class I molecules could be rate-limiting for antigen pres-
entation, and selectivity of this step could be imprinted onto
the pool of dominant and subdominant epitopes. In this re-
view, the current knowledge about the mechanisms underlying
the transport of the peptides from cytosol to the lumen of the
ER is described.
2. Genomic organization of TAP
Studies concerning various cell lines with a strongly reduced
level of MHC class I molecules on the cell surface, strength-
ened the importance of peptide transport into the ER lumen
[4]. Peptides exogenously added or introduced into the ER by
signal sequences were e⁄ciently presented, but these cell lines
were unable to present intracellular antigens on the cell sur-
face. It soon became clear that this defect was due to deletions
in the region of the MHC locus and most likely involved a
gene or genes, that were responsible for delivering peptides to
the lumen of the ER and/or loading newly synthesized class I
molecules with them. In the following, four groups independ-
ently described candidate genes for a factor that would trans-
port peptides across the ER membrane [5^8]. In 1991, a WHO
nomenclature committee for factors in the HLA system re-
named these genes TAP1 (for RING4, PSF1, mtp1 and
HAM1) and TAP2 (for RING11, PSF2, mtp2 and HAM2)
[9]. Alignment between the sequences of TAP1 and TAP2
showed the highest homology in a stretch of 200 amino acids
located at the C-terminus. This region contains three charac-
teristic motifs. The Walker A and B motifs form a highly
conserved ATP-binding cassette. A so-called C-loop, which
consists of six to eight conserved amino acids, is located in
between the Walker A and B motifs. Therefore, the proteins
belong to the superfamily of ATP-binding cassette (ABC)
transporters. A conserved nucleotide-binding domain (NBD)
and a transmembrane domain (TMD) of about six mem-
brane-spanning segments characterize this protein family. A
functional unit comprises two NBDs and two TMDs. Func-
tional impact of TAP1 and TAP2 was proven by transfection
of defective cell lines with TAP2 and/or TAP1 genes, restoring
antigen presenting activity [10,11].
The genomic structures of the human TAP genes have been
established [12]. Each gene is located in the MHC II locus of
chromosome 6, comprises about 10 kb and consists of 11
exons (Fig. 1B) [13]. Eight of these exons are of the same
length, although the intron sizes vary signi¢cantly. The re-
maining three exons 1, 9 and 11 di¡er in length by 100, 3
and 78 nucleotides, respectively. All 11 intron/exon bounda-
ries are identical in their classes and follow the GT/AG rule.
Sequence comparisons from human to salmon TAP1 showed
the expected phylogenetic di¡erences (for example 98.8% ho-
mology of human with gorilla TAP1, 69.2% with hamster and
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40% with salmon). The analysis indicates that the degree of
relatedness between human TAPs is similar to that between
each gene and its homologues in rodents [14]. Although hu-
man TAP1 and TAP2 exhibit only 64% homology at the
protein level, they have a similar predicted membrane topol-
ogy. Therefore, it is speculated that the genes have evolved
from a common ancestral gene by duplication prior to the
development of the adaptive immune system in vertebrates
[15].
3. Regulation of TAP genes
MHC class I molecules are expressed at low levels in most
cells and are strongly induced by cytokines such as interferons
(for review see [16]). Increased expression of MHC class I
molecules correlates with increased CTL function. Therefore,
it was of special interest to study the gene expression of TAP1
and TAP2. Both TAPs are up-regulated by interferon-Q about
10-fold within 24 h, accompanied by an increased peptide
transport capacity. The TAP genes contain no TATA box
motifs in the 5P-£anking sequences, but putative GC-rich ele-
ments (Sp1-binding sites, 128 nucleotides upstream the trans-
lation start codon for TAP1 and 79 nucleotides upstream for
TAP2) [12]. Site directed mutagenesis of the Sp1-binding site
leads to a 3-fold reduction of basal promoter activity of TAP1
[17]. It should be noted that the TAP1 gene is coordinately
regulated by a bidirectional promoter of 593 bp, also directing
the divergently transcribed gene of low molecular mass poly-
peptide 2 (LMP2), a L-type proteasomal subunit, L1. Both
genes are induced by TNF-K via an NF-UB element, which
is also found in the class I response element [18]. The cytokine
induced expression of TAP1 and LMP2 concordantly with
class I genes suggest a mechanism to link transporter levels
with class I production.
4. Structural organization of the TAP complex
As mentioned before, human TAP1 (748 amino acids) and
Fig. 1. A: Antigen processing and presentation via MHC class I molecules. Endogenous proteins are degraded by the proteasome. Peptides are
transported into the lumen of the ER by the TAP complex. Several molecules are involved in assembly and loading of the MHC class I mole-
cules, including calnexin, calreticulin, tapasin and ERp57. Stable MHC-peptide complexes leave the ER via the Golgi compartment to the cell
surface for recognition by cytotoxic T-lymphocytes. Open circles represent folded immunoglobulin domains. B: The location of the TAP genes
in the human MHC class II complex (HLA). The scale is intended as a rough guide only.
FEBS 23105 22-12-99 Cyaan Magenta Geel Zwart
B. Lankat-Buttgereit, R. Tampe¤/FEBS Letters 464 (1999) 108^112 109
human TAP2 (686 amino acids) belong to the superfamily of
ABC transporters, comprising a large number of polytopic
membrane proteins transporting a diverse set of molecules
across membranes in an ATP-dependent manner (for review
see [19,20]). The homology with other members of this family
points to a functional TAP protein either as a homodimer of
TAP1 or TAP2 or a heterodimer. Indeed, immunoprecipita-
tions with antisera directed against TAP1 coprecipitated
TAP1 and TAP2 proteins [21]. Comparisons of the pheno-
types of di¡erent mutant cell lines and heterologous expres-
sion in insect cells and yeast suggest that neither TAP1 nor
TAP2 can form a functional homodimer, indicating that only
a heterodimer is functional [22,23]. Hydrophobicity analysis
and sequence alignments with related ABC transporters point
to a 2U6 transmembrane helix model of TAP, extended by
additional four and three transmembrane helices predicted for
the highly diverse N-terminal domain (Fig. 2) [24]. The hydro-
phobic transmembrane domains are linked to the nucleotide-
binding domains, which contain the conserved Walker A and
B motifs for ATP binding and hydrolysis and, based on this
Fig. 2. Membrane topology of the human TAP complex. The transmembrane helices are predicted from hydrophobicity plots and sequence
alignments with other ABC transporters. The N-terminal domain (N) of TAP1 and TAP2 is very hydrophobic, comprising three or four pre-
dicted transmembrane helices (gray symbols). The nucleotide-binding domain consists of the Walker A and B motifs (A, B) and the so-called
C-loop (C), interacting with a ‘EAA’-like motif (E) in the last cytosolic loop of the membrane-spanning domains. The orange lines illustrate
binding regions for peptides as identi¢ed by photo-crosslinking experiments.
Fig. 3. Model of peptide translocation by the TAP complex. Peptide (dark blue triangles) and ATP/ADP independently bind to TAP in the cy-
tosol. It is unknown, if both NBDs are loaded with ATP. Peptide binding induces a structural reorganization of the TAP complex, triggering
ATP hydrolysis and subsequently translocation of the peptide.
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model, are located in the cytosol. The C-loop interacts with an
‘EAA’-like motif (E) found in the last cytosolic loop of the
membrane-spanning domains [25]. The peptide-binding region
was mapped by photo-crosslinking of peptides to TAP, diges-
tion by trypsin and/or bromocyan and subsequent immuno-
precipitation with antibodies directed against di¡erent epito-
pes of TAP [26]. The analysis of photo-crosslinked fragments
revealed a similar binding region for TAP1 and TAP2, com-
prising the cytosolic loops between TM4 and TM5 and a
carboxy-terminal stretch of about 15 amino acids following
TM6. So far, the peptide translocation pathway is not known,
but it can be speculated that TM5 and TM6 are parts of a
translocation channel.
5. Transport mechanism of TAP
Peptide transport by TAP is a multi-step process [27] (Fig.
3). In a fast bimolecular association step, the peptide binds to
TAP in an ATP-independent manner [28], followed by a slow
isomerization of the TAP complex [29]. It is suggested that
this structural reorganization of the molecule triggers ATP
hydrolysis and peptide translocation across the membrane.
These binding steps primarily determine the selectivity of
TAP. The translocation strictly requires hydrolysis of ATP,
because non-hydrolyzable ATP analogs do not promote pep-
tide transport. ATP and ADP have similar a⁄nities for TAP
[30,31]; therefore, peptide translocation can be inhibited by
ADP. The ATPase activity of TAP is substrate-speci¢c and
tightly coupled to peptide binding, indicating that peptide
binding is a prerequisite for ATP hydrolysis, thereby possibly
preventing waste of ATP without transport of peptides (S.
Gorbulev and R. Tampe¤, manuscript in preparation). A struc-
tural rearrangement of the NBDs seems to function as a mo-
lecular switch to activate the ATPase of TAP. At the moment,
there are no data available, if the NBDs are equal in function
and if they work in a sequential or synchronic manner, there-
by implying whether one or two ATPs are needed for sub-
strate translocation.
6. Substrate speci¢city of TAP
The peptide speci¢city was analyzed by experiments based
on trapping transported peptides in the ER by glycosylation
and on ATP-independent binding assays (for review see [32]).
Those peptides are translocated most e⁄ciently into the ER,
which are similar or slightly larger in length as expected for
MHC class I binding. The contribution of each peptide resi-
due to the a⁄nity for TAP was determined by screening com-
binatorial peptide libraries [33]. With this method, the average
a⁄nity of a randomized peptide mixture with one common
residue is compared to a totally randomized peptide mixture.
The strongest di¡erences were observed for the carboxy-ter-
minal amino acid and the ¢rst three amino-terminal residues.
The amino acids in between do not signi¢cantly contribute to
substrate speci¢city. This binding motif combines maximal
diversity in the epitope where T-cell receptor recognition oc-
curs with maximal binding a⁄nity for antigen processing. The
matched preferences of human TAP and class I suggest a
coevolution of the genes [32].
Although, TAP genes of all species are polymorphic, a
functional polymorphism was so far only found for rat TAP
[34] and for a human TAP2iso splice variant [35]. Mouse
TAP, rat TAP from the RT1u strain and human TAP1/2iso
were described to be selective for hydrophobic carboxy-termi-
ni of the peptide, whereas rat TAP from the RT1a strain and
human TAP seem to be permissive for peptides containing
hydrophobic and basic carboxy-termini [36,37].
7. Loading of peptides from TAP onto MHC molecules
The assembly and loading of MHC class I molecules re-
quire a number of other proteins (for review see [3]). At least
four proteins ^ calnexin, calreticulin, ERp57 and tapasin ^ are
involved in the assembly of heavy chain and L2-microglobulin.
The MHC class I molecules interact with the TAP complex
via an ER-resident type I glycoprotein, named tapasin (Fig.
1A) [38,39]. Tapasin mediates complex formation and the
crosstalk of structural information of MHC and TAP and is
therefore important for class I assembly and editing. Tapasin
has two independent functions: First, it increases the level of
TAP, thereby increasing the e⁄ciency of peptide transport
and, secondly, it associates with MHC class I molecules,
thereby facilitating directly loading and assembly of class I
molecules [40,41]. The MHC-peptide complexes, which are
kinetically stable, can leave the ER to the cell surface.
8. TAP and human diseases
Some viruses are known to interfere with antigen presenta-
tion in infected cells (for review see [42]). For example, the
immediate early gene product ICP47 of herpes simplex virus
type 1 inhibits peptide transport into the ER by blocking
peptide binding to TAP [43^46]. The late expressed ER-resi-
dent transmembrane class I glycoprotein US6 from human
cytomegalovirus inhibits peptide translocation probably by
binding to the ER-luminal part of TAP, because neither pep-
tide binding nor ATP binding to TAP seems to be a¡ected
[47^49].
There is little knowledge about human TAP defects. The
homozygous TAP2 3/3 siblings of one family have reduced
expression of MHC class I molecules on the cell surface and
reduced amounts of cytotoxic T-lymphocytes. On the other
hand, these people do not show an increased susceptibility
to viral infections. The antigens seem to be transported into
the ER lumen in a TAP-independent manner, although under
normal conditions TAP appears to be the dominant pathway
[50]. In some tumor tissues, a down-regulation of TAP
mRNA by an unknown mechanism or mutation of TAP
was observed [51,52]. The suppression of TAP may be a
mechanism for tumor cells to escape the immune response.
The TAPs as peptide transporters are a key link between
antigen processing and presentation. However, many ques-
tions remain open to fully understand the whole process of
T-cell immunity. Further analysis will clarify the signi¢cance
of TAP defects or down-regulation in tumors and, in partic-
ular, the role in the interaction of malignant cells with the
immune system of the host.
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